Endocyte To Present At Upcoming Conferences In March

WEST LAFAYETTE, Ind., Feb. 26, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the following upcoming investment conferences in March:

Cowen and Company 33rd Annual Health Care Conference– Tuesday, March 5, at 9:20 a.m. EST. The conference will be held at the Boston Marriott Copley Place in Boston.

25 th Annual ROTH Conference – Monday, March 18, at 3:30 p.m. EST. The conference will be held at The Ritz-Carlton in Dana Point, Calif.

Webcast information can be accessed under "Events & Presentations" in the Investor Relations section of Endocyte's website at www.endocyte.com . All webcasts will be archived shortly after each live event and a replay will be available on the Company's website for 90 days following the conference.

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

For additional information, please visit Endocyte's website at www.endocyte.com .
CONTACT: Stephanie Ascher         Stern Investor Relations, Inc.         (212) 362-1200         stephanie@sternir.com                  Martina Schwarzkopf, Ph.D.         Russo Partners         (212) 845-4292         martina.schwarzkopf@russopartnersllc.com                  Tony Russo, Ph.D.         Russo Partners         (212) 845-4251         tony.russo@russopartnersllc.com

If you liked this article you might like

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

A Small Biotech Sells for Less Than Cash

A Small Biotech Sells for Less Than Cash

A Small, but Promising Biotech Stock

A Small, but Promising Biotech Stock

4 Biotech Stocks Under $10 to Trade for Breakouts

Why Endocyte (ECYT) Stock Is Declining Today